Literature DB >> 27637646

Intracranial and Spinal Dural Arterio-Venous Fistula (DAVF): A Surgical Series of 107 Patients.

Alessandro Bertuccio1, Chiara Robba2, Giannantonio Spena3, Pietro Primo Versari4.   

Abstract

INTRODUCTION: Dural arteriovenous fistulas (DAVFs) is a challenging condition in vascular neurosurgery. Development of new endovascular techniques has progressively modified treatment strategies; however, surgery is still considered a valid option of treatment of this pathology.
MATERIALS AND METHODS: From a retrospective analysis of our database, we selected 107 patients who underwent surgical treatment for DAVFs. Patients were grouped into five categories according to the Borden and Cognard classifications. Patients and treatment characteristics/outcome is reported.
RESULTS: At admission, 30 (28 %) patients presented with intracranial hemorrhage. Fifteen (14 %) had seizure, whereas nearly half of the patients presented with non-aggressive symptoms, including headache (10, 9.3 %), cognitive impairment (8, 7.5 %), gait disturbance, and imbalance (8, 7.5 %). The majority of patients underwent surgical treatment of fistulas; in some cases, we elected combined surgical-endovascular (obliteration) treatment.
CONCLUSIONS: Management of DAVF requires a multidisciplinary assessment and treatment strategies including surgical, endovascular, and radiosurgical treatment. The data reported confirmed that surgical treatment of DAVFs is associated with a good clinical and radiological (complete occlusion of the fistula) outcome in all cases, with a low rate of complications.

Entities:  

Keywords:  Dural arteriovenous fistulas (DAVF); Hemorrhage; Spinal dural arteriovenous fistulas

Mesh:

Year:  2016        PMID: 27637646     DOI: 10.1007/978-3-319-29887-0_25

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  1 in total

1.  A case of symptomatic spinal dural arteriovenous fistula after high-volume lumbar puncture.

Authors:  Thomas Noh; Rahul Chandra; Jimmy Kim; Ian Lee
Journal:  Surg Neurol Int       Date:  2017-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.